US 12,319,970 B2
Methods for identifying progression of a primary melanoma
Thomas S. Kupper, Belmont, MA (US)
Assigned to The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed by The Brigham and Women's Hospital, Inc., Boston, MA (US)
Filed on Sep. 29, 2022, as Appl. No. 17/956,050.
Application 17/956,050 is a continuation of application No. 16/838,926, filed on Apr. 2, 2020, abandoned.
Claims priority of provisional application 62/828,064, filed on Apr. 2, 2019.
Prior Publication US 2023/0090450 A1, Mar. 23, 2023
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); G01N 2800/52 (2013.01); G01N 2800/54 (2013.01); G01N 2800/56 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating a subject who has primary melanoma, wherein the primary melanoma is cutaneous melanoma and is stage I to IIC, the method comprising:
obtaining a biopsy sample from the primary melanoma;
determining the T cell fraction (TCFr) of said sample, wherein determining the TCFr comprises analyzing T-cell receptor beta (TCR β) gene sequences in substantially every T cell in the sample, and quantitating total nucleated cells and calculating the proportion of T cells in the sample relative to its total number of nucleated cells;
selecting a subject with TCFr below 20% for an aggressive treatment; and
treating said subject with the aggressive treatment, wherein the aggressive treatment is targeted treatment, immunotherapy, chemotherapy, and/or radiation, or a combination thereof.